Evaluation of Cardiotoxic Effects of Bortezomib
- Registration Number
- NCT02026505
- Lead Sponsor
- Oregon Health and Science University
- Brief Summary
The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart.
In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here.
The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
- diagnosis of multiple myeloma
- have a treatment plan involving greater than 4 cycles of bortezomib-based chemotherapy
Exclusion Criteria
- pre-existing history of left ventricular systolic dysfunction
- congestive heart failure
- coronary artery disease
- significant valvular heart disease
- cardiac arrhythmias
- estimated glomerular filtration rate <30 mL/min/1.73m2
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Multiple Myeloma, Bortezomib Bortezomib -
- Primary Outcome Measures
Name Time Method Global longitudinal strain by echocardiography 6 months
- Secondary Outcome Measures
Name Time Method Amino-terminal peptide of procollagen type III 6 months Carboxyl-terminal telopeptide of collagen type I 6 months Amount of late gadolinium enhancement by cardiac MRI 6 months High-sensitivity troponin T 6 months C-reactive protein 6 months Serum NT-proBNP 6 months